In relapsed FLT3-ITD AML post-transplant, treatment with the tyrosine kinase inhibitor sorafenib has demonstrated efficacy, both alone and when combined with azacitidine or DLI (171, 172). Here, FLT3 is linked to acute myeloid leukemia.